research A meta-analysis of chemokines in alopecia areata: recruiting immune cells toward the hair follicle
Alopecia areata involves complex immune dysregulation, mainly driven by Th1 activity, suggesting broader treatment strategies.
Search
for
Sort by
Research
390-420 / 1000+ results
research COMPARATIVE STUDY OF TWO CONCENTRATIONS (2.5MG/ML AND 5 MG/ML) OF INTRALESIONAL TRIAMCINOLONE ACETONIDE IN THE TREATMENT OF ALOPECIA AREATA
2.5 mg/mL TAC is as effective and safe as 5 mg/mL, but 5 mg/mL may improve hair regrowth and density more.
research Real‐life effectiveness and safety of baricitinib in adults with alopecia areata: A multicentre study
Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
research Interleukin 15 Gene Polymorphism in patients with Alopecia Areata
Targeting IL-15 may help treat Alopecia Areata.
research Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
This study evaluated the effectiveness and safety of baricitinib, a JAK-inhibitor, in 50 patients with severe alopecia areata (AA) over 36 weeks in a real-world setting. Patients received 4 mg of baricitinib daily, and results showed a significant reduction in the Severity of Alopecia Tool (SALT) score, with 54.6% achieving a SALT score of 20 or less by week 36. This response rate was higher than that reported in previous phase-III clinical trials. Baricitinib was well-tolerated, with no serious adverse events leading to discontinuation, although some patients experienced hypercholesterolemia and elevated creatine phosphokinase. The study supports the use of baricitinib for severe AA, aligning with clinical trial data, but suggests further research is needed to confirm long-term effectiveness and safety.
research Dual Relief: How Atopic Dermatitis Treatments Affect Alopecia Areata—A Small Retrospective Cohort Study
This small retrospective cohort study investigated the effects of atopic dermatitis (AD) treatments on alopecia areata (AA) in 6 patients, revealing that 5 out of 6 patients (83.3%) experienced significant improvements in both conditions after 6 months of treatment with therapies such as JAK inhibitors (baricitinib and upadacitinib), dupilumab, and systemic corticosteroids. The mean Dermatology Life Quality Index (DLQI) score improved by 91.03%, and the mean Severity of Alopecia Tool (SALT) score improved by 95.65%. However, 2 patients experienced worsening AA symptoms with dupilumab, indicating the need for personalized treatment strategies and careful monitoring. The study highlights the potential of JAK inhibitors in managing these comorbid conditions and calls for larger studies to validate these findings.
research SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss
The updated SALT II tool offers a more precise way to measure scalp hair loss.
research Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents with Alopecia Areata
Alopecia areata affects quality of life more in adolescents than adults.
research Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study
Baseline severity and relapse history affect alopecia areata treatment and recurrence.
research Hearing impairment in patients with alopecia areata
Alopecia areata may lead to hearing loss.
research Psychosocial impact of wigs or hairpieces on perceived quality of life level in female patients with alopecia areata
Wearing wigs or hairpieces improves self-esteem, adaptability, and competence in women with alopecia areata.
research Salt-losing tubulopathy and chronic dermatitis
Genetic testing for EGFR mutations is crucial in similar cases.
research Quality of life in patients with alopecia areata: a hospital‐based cross‐sectional study
Alopecia areata significantly lowers quality of life, especially in personal and social areas, and more so if the patient is also depressed.
research Evaluation of quality of life scores and family impact scales in pediatric patients with alopecia areata: a cross‐sectional cohort study
Alopecia areata greatly affects the quality of life for children and their families.
research Alopecia areata. Diagnostic and therapeutic recommendations of the Polish Society of Dermatology. Part 2: Treatment
The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
research Current Diagnostic and Therapeutic Practices in Alopecia Areata in Two Mediterranean Countries: A Survey-Based Study
There are significant gaps and inconsistencies in diagnosing and treating alopecia areata in Greece and Italy.
research Reduction of telogen rate and increase of hair density in androgenetic alopecia by a cosmetic product: Results of a randomized, prospective, vehicle‐controlled double‐blind study in men
Cosmetic foam product reduces hair loss and increases hair density in men.
research Gene Expression of Osteopontin in Alopecia Areata? A Case-Controlled Study
People with alopecia areata have higher levels of osteopontin, which might be important in the disease's development, but this doesn't relate to how severe the disease is.
research Guidelines for clinical trials of frontal fibrosing alopecia: consensus recommendations from the International FFA Cooperative Group (IFFACG)*
Experts agreed on guidelines to improve research on Frontal Fibrosing Alopecia.
research Phosphodiesterase (PDE) Inhibitors for the Treatment of Inflammatory Skin Conditions
PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.
research Assessment of Alopecia Areata Disease Severity in Pediatric Patients
New tools help doctors better assess and treat alopecia areata in kids by considering more than just hair loss.
research BH15 The burden of alopecia areata: examining baseline health-related quality of life and clinical assessment tools
Alopecia areata greatly affects quality of life, especially mental health, and newer assessment tools better capture this impact than older ones.
research Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
research Hair density response to photobiomodulation in canine alopecia X is measured reliably with an ordinal scale: a randomized, controlled, double-blind study
Photobiomodulation did not significantly improve hair density in dogs with alopecia X.
research Polycystic ovary syndrome and the differential diagnosis of hyperandrogenism
The document concludes that careful evaluation is needed to diagnose PCOS correctly due to similar symptoms in other conditions, and accurate testosterone level measurement is crucial.
research What Is the Male Polycystic Ovary Syndrome Phenotype?
Men can have genetic risks for PCOS-related traits like obesity and diabetes.
research Does zinc have a role in alopecia areata? A clinic-biochemical study
Zinc levels are not significantly linked to the presence or severity of alopecia areata.
research Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
research Pediatric and Adolescent Alopecia Areata Treated with JAK Inhibitors: Balancing Efficacy and Safety Across Clinical Trials
JAK inhibitors effectively regrow hair in children with alopecia areata and are safe to use.
research Race and Ethnicity Sub-Groups of Alopecia Areata Patients have Differing Clinical Characteristics: TARGET-DERM AA
Alopecia areata severity and symptoms vary by race and ethnicity.